Abiomed (ABMD) Halted Ahead of FDA Meeting on Blood Pumps
Abiomed, Inc. (NASDAQ: ABMD) halted ahead of FDA advisory committee meeting over nonroller-type cardiopulmonary bypass blood pumps.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Titan Pharma (TTNP) Announces Receipt of FDA Approval for Probuphine as Opioid Dependence Treatment
- Leerink Remains Cautious on Ionis Pharmaceuticals (IONS) Following Conference Call
- Minerva Neurosciences (NERV) Rips 200% Higher on Positive Phase MIN-117 Trial Results
Create E-mail Alert Related CategoriesFDA, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!